



## MediWound to Report Second Quarter 2023 Financial Results

August 7, 2023

### Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time

YAVNE, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2023 on Tuesday, August 15, 2023.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.

Dial-in and call details are as follows:

#### **Conference Call & Webcast Details**

Toll-Free: 1-833-630-1956  
Israel: 1-80-921-2373  
International: 1-412-317-1837  
Webcast: [Click HERE](#)

To access the call, participants should dial the **applicable** telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

#### **About MediWound**

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

MediWound's first drug, NexoBrid<sup>®</sup>, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company's lead drug under development, EscharEx<sup>®</sup>. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the \$300 million monopoly legacy drug and an opportunity to expand the market. MediWound's pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study.

For more information visit [www.mediwound.com](http://www.mediwound.com) and follow the Company on [LinkedIn](#).

#### **Contacts:**

Hani Luxenburg  
Chief Financial Officer  
MediWound Ltd.  
[ir@mediwound.com](mailto:ir@mediwound.com)

Monique Kosse  
Managing Director, LifeSci Advisors  
212-915-3820  
[monique@lifesciadvisors.com](mailto:monique@lifesciadvisors.com)